Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12048608 | 0.84 | KDM4E (0.45) | SMN1; SMN2ALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL16334324 | 0.81 | HSD11B1 (0.45) | HSD11B1SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7092726 | 0.81 | HSD11B1 (0.45) | HSD11B1SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL12656988 | 0.79 | HSD11B1 (0.47) | HSD11B1SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL13990506 | 0.78 | HSD11B1 (0.43) | HSD11B1SMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL15668834 | 0.77 | HSD11B1 (0.45) | HSD11B1SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL15669044 | 0.77 | HSD11B1 (0.42) | HSD11B1SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7710680 | 0.75 | HSD11B1 (0.44) | HSD11B1SMN1; SMN2ALDH1A1MAPTCYP1A2 | |
| SCHEMBL8116578 | 0.75 | KDM4E (0.44) | HSD11B1ALDH1A1HPGDPDE5AFFAR4 | |
| SCHEMBL245135 | 0.74 | NOS3 (0.50) | ALDH1A1MAPTL3MBTL1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695132-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | HSD11B1 244/4885SMN1; SMN2 1065/4885ALDH1A1 1709/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | HSD11B1 1880/4885SMN1; SMN2 3812/4885ALDH1A1 2289/4885 |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | HSD11B1 4357/4885SMN1; SMN2 4778/4885ALDH1A1 2717/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | HSD11B1 300/4885SMN1; SMN2 2352/4885ALDH1A1 684/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | HSD11B1 2273/4885SMN1; SMN2 4304/4885ALDH1A1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.